Valuation: ALLOVIRPAR

Market Cap 49.21M 43.26M 40.27M 36.98M 69.45M 4.72B 70.36M 479M 187M 2.33B 185M 181M 8.05B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.73M -56.53M -51.91M -97.48M -6.62B -98.77M -672M -262M -3.27B -259M -254M -11.31B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-4.02%
Current month-63.51%
Current year-63.51%
3 years 3.5
Extreme 3.5
86.25
5 years 3.5
Extreme 3.5
607.43
10 years 3.5
Extreme 3.5
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -167M -156M -143M -269M -18.26B -272M -1.85B -723M -9.02B -715M -699M -31.17B -58.77M -51.66M -48.09M -44.17M -82.93M -5.64B -84.03M -572M -223M -2.78B -221M -216M -9.62B
Net Debt -157M -138M -128M -118M -221M -15.01B -224M -1.52B -595M -7.41B -588M -575M -25.62B -118M -104M -96.8M -88.9M -167M -11.34B -169M -1.15B -449M -5.6B -444M -434M -19.36B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
26-07-27 US$3.580 -4.02% 71,676
26-07-24 US$3.730 -4.85% 157,759
26-07-23 US$3.920 -3.69% 137,698
26-07-22 US$4.070 +0.74% 97,363
26-07-21 US$4.040 +1.00% 395,382
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock